We engage and support talented researchers with proven or high potential to make a significant impact, who are dedicated to patient-focused research, collaborate across disciplines and institutions, and actively partner with others to accelerate collective progress in tau research.
In September 2025, the Tau Consortium (TC) established 5-year strategic goals that aim to enable targeted, impactful advancements in the search for treatments for primary tauopathies.
The Tau Consortium 5-Year Goals
- Foster Translational Mechanisms: Maintain a robust portfolio balancing compelling pilot projects with mature, translational programs, with a goal of transitioning at least three validated TC targets to the TC discovery pipeline. Read more about the RCF’s current basic research networks.
- Identify Liquid Biomarkers: Facilitate the identification of at least one diagnostic or disease progression biomarker that correlates to primary tauopathy as the underlying clinical diagnosis. Discover how biomarkers can diagnose and track tauopathy progression.
- Develop Neuroimaging Biomarker: Forge a new RCF-developed tau PET ligand with <1nM affinity to 4R tau entering a first-in-human study. Explore the values of PET imaging tools.
- Advance Therapeutics: Advance two RCF-supported programs to IND-enabling studies. Find out more about our drug discovery portfolio.
- Strengthen Clinical Readiness: Ensure robust access to diverse patients and associated resources by mobilizing a TC Clinical Development Advisory Team. Take a closer look at our clinical readiness programs.
Scientific Advisory Board
The Scientific Advisory Board (SAB) of the Tau Consortium is composed of internationally recognized experts in neurodegenerative disease research. This group provides scientific oversight and critical evaluation of research initiatives to ensure the consortium remains at the forefront of tau-related discovery and therapeutic development.
